Beta Bionics CFO exercises options and sells 5,587 shares

Beta Bionics, Inc. Chief Financial Officer Stephen Feider reported an exercise-and-sell transaction on August 19, 2025.

Rhea-AI Filing Summary

Beta Bionics, Inc. Chief Financial Officer Stephen Feider reported an exercise-and-sell transaction on August 19, 2025. He exercised employee stock options for 5,587 shares of common stock at $5.10 per share, then sold the same 5,587 shares at a weighted average price of $17.034505, pursuant to a Rule 10b5-1 plan adopted May 15, 2025. Following the transaction, he holds 45,503 shares of common stock directly and has 104,108 option shares reported as outstanding.

Insights

Financial Analyst

TL;DR: CFO executed an option acquisition at a low strike and sold the same number of shares under a 10b5-1 plan, reducing direct holdings modestly.

Feider exercised or was granted rights to 5,587 shares at a $5.10 price and sold 5,587 shares under a pre-established Rule 10b5-1 plan at a weighted average of $17.0345. The transactions are cash-positive for the reporting person and dilutive only to the extent of option exercises when shares are issued, but here the sale appears to be from shares sold under the plan. The reduction in direct holdings from 51,090 to 45,503 represents a meaningful but not large percentage of his direct stake.

Corporate Governance Expert

TL;DR: Transactions follow a formal 10b5-1 plan, indicating pre-planned disposition rather than ad hoc insider selling.

The sale is explicitly reported as pursuant to a Rule 10b5-1 plan adopted May 15, 2025, which provides affirmative defense from insider trading claims. That procedural compliance is important for governance and disclosure standards. Vesting terms (48 monthly installments from 09/14/2023) are disclosed, supporting transparency about how additional equity will become available to the officer over time.

Insider Trade Summary

Exercise and Sale: 5,587 shares ($67K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Feider Stephen

Role Chief Financial Officer

Sold 5,587 shs ($95K)

Approx. gross sale proceeds $95K

Approx. exercise cost $28K

Approx. pre-tax spread $67K

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (right to buy)	5,587	$0.00	$0.00
Exercise	Common Stock	5,587	$5.10	$28K
Sale	Common Stock	5,587	$17.0345	$95K

Holdings After Transaction: Employee Stock Option (right to buy) — 104,108 contracts (Direct); Common Stock — 45,503 shares (Direct)

Footnotes (3)

1. F1. Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 15, 2025.
2. F2. The weighted average sale price for the transaction reported was $17.034505 and the range of prices were between $17.00 and $17.095. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
3. F3. The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023.

Key Figures

Options Exercised: 5,587 shares Exercise Price: $5.10 per share Shares Sold: 5,587 shares +3 more

6 metrics

Options Exercised 5,587 shares Employee stock option exercise on August 19, 2025

Exercise Price $5.10 per share Price for the 5,587-option exercise into common stock

Shares Sold 5,587 shares Common stock sold on August 19, 2025

Weighted Average Sale Price $17.034505 per share Sale price, with trades between $17.00 and $17.095

Post-Transaction Common Holdings 45,503 shares Direct common stock held after the reported transactions

Options Outstanding After Exercise 104,108 shares Total option shares reported following the derivative exercise

Key Terms

Rule 10b5-1 Plan, Employee Stock Option, weighted average sale price, vest in 48 equal monthly installments

4 terms

Rule 10b5-1 Plan financial

"Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 15, 2025."

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

Employee Stock Option financial

"security_title "Employee Stock Option (right to buy)" for the derivative transaction."

An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.

weighted average sale price financial

"The weighted average sale price for the transaction reported was $17.034505."

vest in 48 equal monthly installments financial

"The shares subject to this option shall vest in 48 equal monthly installments."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Beta Bionics (BBNX) CFO Stephen Feider report?

CFO Stephen Feider exercised 5,587 stock options at $5.10 and sold 5,587 common shares at a weighted average price of $17.034505 on August 19, 2025, in an exercise-and-sell transaction.

How many Beta Bionics (BBNX) shares did Stephen Feider sell and at what price?

Stephen Feider sold 5,587 shares of Beta Bionics common stock at a weighted average price of $17.034505 per share, with individual sales ranging between $17.00 and $17.095.

Was Stephen Feider’s sale of Beta Bionics (BBNX) shares under a Rule 10b5-1 plan?

Yes. The filing states the shares sold were pursuant to a Rule 10b5-1 Plan adopted on May 15, 2025, indicating the trades were made under a pre-arranged trading plan.

How many Beta Bionics (BBNX) shares does Stephen Feider hold after this Form 4 transaction?

After the reported transactions, Stephen Feider directly holds 45,503 shares of Beta Bionics common stock, as disclosed in the post-transaction holdings information.

What stock options did Stephen Feider exercise in Beta Bionics (BBNX)?

He exercised an employee stock option covering 5,587 shares of Beta Bionics common stock at an exercise price of $5.10 per share; the option vests in 48 equal monthly installments from September 14, 2023.

How many Beta Bionics (BBNX) options remain outstanding for Stephen Feider after the transaction?

Following the option exercise, the filing reports 104,108 option shares remaining outstanding for Stephen Feider, reflecting his continuing derivative position in Beta Bionics stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/20/2025 - 09:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Feider Stephen

(Last) (First) (Middle)

C/O BETA BIONICS, INC.

11 HUGHES

(Street)

IRVINE CA 92618

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/19/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/19/2025		M		5,587	A	$5.1	51,090	D
Common Stock	08/19/2025		S(1)		5,587	D	$17.0345(2)	45,503	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$5.1	08/19/2025		M			5,587	(3)	09/13/2033	Common Stock	5,587	$0	104,108	D

Explanation of Responses:

1. Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 15, 2025.

2. The weighted average sale price for the transaction reported was $17.034505 and the range of prices were between $17.00 and $17.095. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

3. The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023.

	/s/ Stephen Feider	08/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.